Acquired by Cyclo Therapeutics Inc. in Jan 2024
AMTI - Applied Molecular Transport Inc.
NASDAQ
->
Healthcare
->
Biotechnology
South San Francisco,
United States
Type: Equity
AMTI price evolution
AMTI
| (in millions $) | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 | 31 Jan 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $18.1 | $22.46 | $42.69 | $62.06 |
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $18.82 | $23.32 | $46.32 | $64.02 |
| Long term investments | ||||
| Property, plant & equipment | $1.2 | $1.52 | $37.81 | $41.99 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $1.2 | $1.64 | $36.98 | $43.43 |
| Total investments | ||||
| Total assets | $20.02 | $24.96 | $83.3 | $107.45 |
| Current liabilities | ||||
| Accounts payable | $0.16 | $0.16 | $0.87 | $1.58 |
| Deferred revenue | ||||
| Short long term debt | $1.35 | $1.46 | $4.96 | $4.84 |
| Total current liabilities | $3.77 | $3.82 | $16.82 | $15.09 |
| Long term debt | $0.25 | $30.09 | $0.29 | |
| Total noncurrent liabilities | $0.5 | $30.33 | $31.52 | |
| Total debt | $1.35 | $1.71 | $35.05 | $36.12 |
| Total liabilities | $3.77 | $4.31 | $47.15 | $46.61 |
| Shareholders' equity | ||||
| Retained earnings | -$418.16 | -$411.22 | -$393.89 | -$365.97 |
| Other shareholder equity | ||||
| Total shareholder equity | $16.24 | $20.65 | $36.14 | $60.84 |
| (in millions $) | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $62.06 | $160.85 | $5.95 | $12.84 |
| Short term investments | $124.03 | $19.68 | ||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $64.02 | $167.1 | $131.5 | $33.45 |
| Long term investments | $0.25 | |||
| Property, plant & equipment | $41.99 | $45.14 | $8.45 | $4.09 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $43.43 | $46.94 | $8.68 | $5.08 |
| Total investments | $124.03 | $19.93 | ||
| Total assets | $107.45 | $214.04 | $140.18 | $38.53 |
| Current liabilities | ||||
| Accounts payable | $1.58 | $2.21 | $3.17 | $2.67 |
| Deferred revenue | ||||
| Short long term debt | $4.84 | $3.82 | $0.23 | |
| Total current liabilities | $15.09 | $14.26 | $7.66 | $4.04 |
| Long term debt | $0.29 | $35.95 | $0.4 | $0.1 |
| Total noncurrent liabilities | $31.52 | $36.19 | $0.85 | $0.58 |
| Total debt | $36.12 | $39.77 | $0.64 | |
| Total liabilities | $46.61 | $50.45 | $8.51 | $4.62 |
| Shareholders' equity | ||||
| Retained earnings | -$365.97 | -$239.65 | -$139.36 | -$72.79 |
| Other shareholder equity | $0.03 | $0.01 | ||
| Total shareholder equity | $60.84 | $163.59 | $131.67 | -$71.7 |
| (in millions $) | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 | 31 Dec 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $0.25 | $2.56 | $12.99 | $14.44 |
| Selling, general & administrative | $7.01 | $7.04 | $6.75 | $8.65 |
| Total operating expenses | $7.22 | $17.73 | $28.48 | $23.09 |
| Operating income | -$7.22 | -$17.73 | -$28.48 | -$23.09 |
| Income from continuing operations | ||||
| EBIT | -$6.94 | -$17.33 | -$28.5 | -$22.6 |
| Income tax expense | ||||
| Interest expense | -$0.58 | |||
| Net income | ||||
| Net income | -$6.94 | -$17.33 | -$27.92 | -$22.6 |
| Income (for common shares) | -$6.94 | -$17.33 | -$27.92 | -$22.6 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $89.83 | $71.45 | $53.94 | $24.32 |
| Selling, general & administrative | $37.39 | $29.34 | $12.75 | $3.97 |
| Total operating expenses | $127.22 | $100.79 | $66.68 | $28.29 |
| Operating income | -$127.22 | -$100.79 | -$66.68 | -$28.29 |
| Income from continuing operations | ||||
| EBIT | -$126.33 | -$100.29 | -$66.56 | -$28.04 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$126.33 | -$100.29 | -$66.56 | -$28.04 |
| Income (for common shares) | -$126.33 | -$100.29 | -$66.56 | -$28.04 |
| (in millions $) | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 | 31 Dec 2022 |
|---|---|---|---|---|
| Net income | -$6.94 | -$17.33 | -$27.92 | -$22.6 |
| Operating activities | ||||
| Depreciation | $0.33 | $1.38 | $2.67 | $2.52 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $2.53 | $1.83 | $3.22 | $4.96 |
| Total cash flows from operations | -$4.4 | -$21.52 | -$19.3 | -$14.82 |
| Investing activities | ||||
| Capital expenditures | $0.04 | $1.47 | -$0.01 | -$0.01 |
| Investments | ||||
| Total cash flows from investing | $0.04 | $1.47 | -$0.01 | -$0.01 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.01 | $0.08 | ||
| Net borrowings | -$0.18 | -$0.07 | -$0.06 | |
| Total cash flows from financing | -$0.18 | -$0.07 | -$0.05 | |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$4.35 | -$20.23 | -$19.37 | -$14.88 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Net income | -$126.33 | -$100.29 | -$66.56 | -$28.04 |
| Operating activities | ||||
| Depreciation | $11.42 | $7.61 | $1.84 | $0.71 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $23.17 | $16.7 | $3.06 | $0.47 |
| Total cash flows from operations | -$93.9 | -$82.61 | -$58.89 | -$26.97 |
| Investing activities | ||||
| Capital expenditures | -$4.15 | -$1.86 | -$5.32 | -$2.15 |
| Investments | $124.07 | -$103.97 | -$19.98 | |
| Total cash flows from investing | -$4.15 | $122.21 | -$109.29 | -$22.13 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.41 | $116.23 | $165.33 | |
| Net borrowings | -$0.27 | -$0.23 | -$0.09 | -$0.09 |
| Total cash flows from financing | -$0.73 | $115.3 | $161.3 | $41.65 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$98.78 | $154.9 | -$6.88 | -$7.45 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 40.90M |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$68.47M |
| EBIT | -$75.36M |
| Net Income | -$74.79M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | 0.40 |
| Cash/Share | 0.44 |
| EPS | -$1.83 |
|---|---|
| ROA | -126.91% |
| ROE | -223.46% |
| Debt/Equity | 0.77 |
|---|---|
| Net debt/EBITDA | 0.21 |
| Current ratio | 4.99 |
| Quick ratio | 4.99 |